Fig. 1From: Intravitreal bevacizumab plus propranolol for neovascular age-related macular degeneration (the BEVALOL study): a phase I clinical trialERG changes. Full-field ERG baseline and after 12 weeks of follow up showed no significant difference between before and after treatmentBack to article page